Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Diffuse Large B-Cell Lymphoma Specialty Channel

Diffuse Large B-Cell Lymphoma
Specialty Channel
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology
News
Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma
04/09/2024

Amber Denham

Amber Denham
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short...
04/09/2024
Oncology
Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
R-CHOP Followed by R-ICE Regimen vs Standard-of-Care Therapy for Patients With Non-GCB DLBCL
03/12/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses...
03/12/2024
Oncology
News
Lisocabtagene Maraleucel Shows Continued Efficacy, Manageable Safety for Patients with R/R LBCL
02/28/2024

Amber Denham

Amber Denham
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up...
02/28/2024
Oncology
Quiz
Blinatumomab After ASCT as a Treatment Option Among Patients With Relapsed DLBCL
02/27/2024
02/27/2024
Oncology
News
Polatuzumab Vedotin Plus Rituximab and Lenalidomide Efficacy Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
02/21/2024

Amber Denham

Amber Denham
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with...
02/21/2024
Oncology
News
Blinatumomab Consolidation After Auto-SCT Yields Safety, Tolerability Among Patients With Relapsed DLBCL
02/02/2024

Amber Denham

Amber Denham
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after...
02/02/2024
Oncology
Gilles Salles, MD, PhD
Videos
Examining Factors to Consider in the Treatment of Patients With Indolent B-Cell Lymphomas
01/15/2024

Featuring Gilles Salles, MD, PhD

Featuring Gilles Salles, MD, PhD ...
Gilles Salles, MD, PhD, offers advice for fellow oncologists in the B-cell lymphoma space, highlighting the need for strategically chosen therapies to minimize the risk of transformations.
Gilles Salles, MD, PhD, offers advice for fellow oncologists in the B-cell lymphoma space, highlighting the need for strategically chosen therapies to minimize the risk of transformations.
Gilles Salles, MD, PhD, offers...
01/15/2024
Oncology
News
Rituximab Plus Lenalidomide Treatment Shows Promise for Older Patients with DLBCL
01/11/2024

Amber Denham

Amber Denham
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and...
01/11/2024
Oncology
News
Controlling Nutritional Status Score Shows Prognostic Value Among Older Patients With DLBCL
01/03/2024

Amber Denham

Amber Denham
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in...
01/03/2024
Oncology

Advertisement

News

News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma
04/09/2024

Amber Denham

Amber Denham
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short...
04/09/2024
Oncology
News
Lisocabtagene Maraleucel Shows Continued Efficacy, Manageable Safety for Patients with R/R LBCL
02/28/2024

Amber Denham

Amber Denham
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up...
02/28/2024
Oncology
News
Polatuzumab Vedotin Plus Rituximab and Lenalidomide Efficacy Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
02/21/2024

Amber Denham

Amber Denham
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with...
02/21/2024
Oncology
News
Blinatumomab Consolidation After Auto-SCT Yields Safety, Tolerability Among Patients With Relapsed DLBCL
02/02/2024

Amber Denham

Amber Denham
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after...
02/02/2024
Oncology
News
Rituximab Plus Lenalidomide Treatment Shows Promise for Older Patients with DLBCL
01/11/2024

Amber Denham

Amber Denham
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and...
01/11/2024
Oncology
News
Controlling Nutritional Status Score Shows Prognostic Value Among Older Patients With DLBCL
01/03/2024

Amber Denham

Amber Denham
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in...
01/03/2024
Oncology
News
CD5 Biomarker Effective for Identifying DLBCL Subtypes Sensitive to BTK Inhibitor Therapy
01/03/2024

Amber Denham

Amber Denham
A CD5 gene expression signature was found to be useful in identifying diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies, according to a recent study.
A CD5 gene expression signature was found to be useful in identifying diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies, according to a recent study.
A CD5 gene expression signature...
01/03/2024
Oncology
Conference Coverage
R-CHOP Plus Tazemetostat Therapy Feasible Among Older Patients With Newly Diagnosed DLBCL
12/11/2023

Amber Denham

Amber Denham
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2...
12/11/2023
Oncology
Conference Coverage
Glofitamab Plus Polatuzumab Vedotin Demonstrates Durable Responses Among Pretreated Patients With DLBCL, Including HGBCL
12/11/2023

Amber Denham

Amber Denham
Glofitamab plus polatuzumab vedotin demonstrated high response rates and durable responses among heavily pre-treated patients with DLBCL, including patients with HGBCL and with prior CAR T-cell therapy, according to updated phase 1b/2 study...
Glofitamab plus polatuzumab vedotin demonstrated high response rates and durable responses among heavily pre-treated patients with DLBCL, including patients with HGBCL and with prior CAR T-cell therapy, according to updated phase 1b/2 study...
Glofitamab plus polatuzumab...
12/11/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Interactive Features

Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology
Quiz
Blinatumomab After ASCT as a Treatment Option Among Patients With Relapsed DLBCL
02/27/2024
02/27/2024
Oncology
Quiz
Treating DLBCL With Tafasitamab Plus R-CHOP, With or Without Lenalidomide
12/15/2023
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to...
12/15/2023
Oncology
Quiz
Acalabrutinib Plus Danvatirsen for R/R DLBCL
12/05/2023
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of...
12/05/2023
Oncology
Quiz
Standard vs 4-Cycle Regimen of R-CHOP for Non-Bulky, Low-Risk DLBCL
11/07/2023
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a...
11/07/2023
Oncology
Quiz
Simplified CIRS-Derived Comorbidity Index For DLBCL Patients Indicated for CAR T-Cell Therapy
10/18/2023
True or False: A simplified cumulative illness rating scale (CIRS)-derived comorbidity index was able to assess and predict adverse outcomes among patients with R/R DLBCL indicated for chimeric antigen receptor T-cell (CAR T) therapy.
True or False: A simplified cumulative illness rating scale (CIRS)-derived comorbidity index was able to assess and predict adverse outcomes among patients with R/R DLBCL indicated for chimeric antigen receptor T-cell (CAR T) therapy.
True or False: A simplified...
10/18/2023
Oncology
Quiz
Treating R/R DLBCL With Mosunetuzumab
10/03/2023
True or False: Mosunetuzumab demonstrated high efficacy and manageable safety among patients with R/R DLBCL, including those previously treated with CAR T-cell therapy.
True or False: Mosunetuzumab demonstrated high efficacy and manageable safety among patients with R/R DLBCL, including those previously treated with CAR T-cell therapy.
True or False: Mosunetuzumab...
10/03/2023
Oncology
Quiz
BET Inhibitor Trotabresib for Heavily-Pretreated R/R DLBCL
09/11/2023
True or False: Findings from a phase 1 trial indicated that BET protein inhibitor trotabresib monotherapy demonstrated potential, and antitumor activity, among patients with heavily pretreated relapsed/refractory DLBCL, as well as patients...
True or False: Findings from a phase 1 trial indicated that BET protein inhibitor trotabresib monotherapy demonstrated potential, and antitumor activity, among patients with heavily pretreated relapsed/refractory DLBCL, as well as patients...
True or False: Findings from a...
09/11/2023
Oncology
Quiz
High-Dose Chemotherapy and Auto-HSCT in First Remission for Intermediate/High-Risk Stage IV DLBCL
09/05/2023
True or False: High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem-cell transplantation (auto-HSCT) in the first remission yielded effective results and improved prognosis among patients with intermediate/high-risk stage...
True or False: High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem-cell transplantation (auto-HSCT) in the first remission yielded effective results and improved prognosis among patients with intermediate/high-risk stage...
True or False: High-dose...
09/05/2023
Oncology
Quiz
FDA Approval of Polatuzumab Vedotin Plus R-CHP for Patients With DLBCL
06/02/2023
True or False: The FDA granted approval to polatuzumab vedotin in combination with R-CHP for the treatment of patients with previously untreated DLBCL, not otherwise specified, or high-grade B-cell lymphoma and an International Prognostic...
True or False: The FDA granted approval to polatuzumab vedotin in combination with R-CHP for the treatment of patients with previously untreated DLBCL, not otherwise specified, or high-grade B-cell lymphoma and an International Prognostic...
True or False: The FDA granted...
06/02/2023
Oncology
Quiz
Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer
08/08/2024
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance...
08/08/2024
Oncology
Quiz
Recommended Dostarlimab Dose for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/08/2024
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase...
08/08/2024
Oncology
Quiz
Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer
08/05/2024
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to...
08/05/2024
Oncology
Quiz
Improving Long-Term Outcomes for Patients With HER2-Positive Early-Stage Invasive Breast Cancer
07/15/2024
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis...
07/15/2024
Oncology
Quiz
Ibrutinib Plus Venetoclax For Patients With TP53-Mutated Mantle Cell Lymphoma
07/12/2024
07/12/2024
Oncology
Quiz
Weekly Combination Therapy for Patients With R/R Multiple Myeloma
07/11/2024
07/11/2024
Oncology
Quiz
Examining the Efficacy of Azacitidine Plus Ruxolitinib in Myelofibrosis Treatment
07/03/2024
07/03/2024
Oncology
Quiz
FDA Approval of Lisocabtagene Maraleucel for MCL
07/01/2024
07/01/2024
Oncology
Quiz
Carboplatin Plus Standard Chemotherapy for Patients With Early-Stage Triple-Negative Breast Cancer
06/28/2024
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in...
06/28/2024
Oncology
Quiz
Treatment Options for a Patient With Early-Stage Non-Small Cell Lung Cancer
06/26/2024
What adjuvant treatment would you recommend?
What adjuvant treatment would you recommend?
What adjuvant treatment would...
06/26/2024
Oncology

Advertisement

Recent News

News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma
04/09/2024

Amber Denham

Amber Denham
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short...
04/09/2024
Oncology
News
Lisocabtagene Maraleucel Shows Continued Efficacy, Manageable Safety for Patients with R/R LBCL
02/28/2024

Amber Denham

Amber Denham
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up...
02/28/2024
Oncology
News
Polatuzumab Vedotin Plus Rituximab and Lenalidomide Efficacy Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
02/21/2024

Amber Denham

Amber Denham
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with...
02/21/2024
Oncology
News
Blinatumomab Consolidation After Auto-SCT Yields Safety, Tolerability Among Patients With Relapsed DLBCL
02/02/2024

Amber Denham

Amber Denham
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after...
02/02/2024
Oncology
News
Rituximab Plus Lenalidomide Treatment Shows Promise for Older Patients with DLBCL
01/11/2024

Amber Denham

Amber Denham
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and...
01/11/2024
Oncology
News
Controlling Nutritional Status Score Shows Prognostic Value Among Older Patients With DLBCL
01/03/2024

Amber Denham

Amber Denham
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in...
01/03/2024
Oncology
News
CD5 Biomarker Effective for Identifying DLBCL Subtypes Sensitive to BTK Inhibitor Therapy
01/03/2024

Amber Denham

Amber Denham
A CD5 gene expression signature was found to be useful in identifying diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies, according to a recent study.
A CD5 gene expression signature was found to be useful in identifying diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies, according to a recent study.
A CD5 gene expression signature...
01/03/2024
Oncology
Conference Coverage
R-CHOP Plus Tazemetostat Therapy Feasible Among Older Patients With Newly Diagnosed DLBCL
12/11/2023

Amber Denham

Amber Denham
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2...
12/11/2023
Oncology
Conference Coverage
Glofitamab Plus Polatuzumab Vedotin Demonstrates Durable Responses Among Pretreated Patients With DLBCL, Including HGBCL
12/11/2023

Amber Denham

Amber Denham
Glofitamab plus polatuzumab vedotin demonstrated high response rates and durable responses among heavily pre-treated patients with DLBCL, including patients with HGBCL and with prior CAR T-cell therapy, according to updated phase 1b/2 study...
Glofitamab plus polatuzumab vedotin demonstrated high response rates and durable responses among heavily pre-treated patients with DLBCL, including patients with HGBCL and with prior CAR T-cell therapy, according to updated phase 1b/2 study...
Glofitamab plus polatuzumab...
12/11/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement